Since elevated levels of both Gal-1 and Gal-3 are exhibited by patients with osteosarcoma [162,163,164,165], and long-term survivors of osteosarcoma show higher risks for OP prevalence and OF [166,167], a multifactorial approach aimed to target these Gals in osteoporotic patients with osteosarcoma, whose progression is favored by a state of chronic inflammation and aging/senescence-induced genes [168,169], could be hypothesized as an innovative therapeutic approach. This evidence concerns the gene LGALS1 and osteosarcoma.